Abstract Providers and patients encounter challenges related to the management of Variants of Unknown Significance (VUS). A VUS introduces new counseling dilemmas for the understanding and psychosocial impact of uncertain genetic test results. This descriptive study uses Mishel's theory of uncertainty in illness to explore the experience of individuals who have received a VUS as part of the genetic testing process. Semi-structured interviews were conducted with 27 adult individuals who received a VUS for Lynch syndrome mismatch repair genes between 2002 and 2013. The interviews were transcribed and analyzed. Most individuals recalled their result and perceived various types of uncertainty associated with their VUS. Half of the participants appraised their variant as a danger and implemented coping strategies to reduce the threat of developing cancer. Mobilizing strategies to reduce their risk included vigilant cancer surveillance, information seeking and notifying relatives. The majority of participants were unaware of the possibility of a VUS before receiving their result and expected reclassification over time. These results provide insight into the ways healthcare providers can support patients who receive VUS for Lynch syndrome. Findings also provide direction for future work that can further explicate the impact of receiving a VUS.
Introduction
Uncertainty exists when situations or outcomes are ambiguous, complex or unpredictable. Uncertainty can be conceptualized as a state of mind where there is a lack of knowledge about some aspect of reality, as well as awareness about that lack of knowledge (Han, Klein, & Arora, 2011) . According to Mishel's Theory of Uncertainty in Illness (1988) , uncertainty occurs when a patient fails to form cognitive schema for illness events. Uncertainty might also be experienced when a person assesses the probability of an event or outcome, such as risk of illness or disease (Babrow, Kasch, & Ford, 1998; Luther & Crandall, 2011) . When health situations present uncertain characteristics, patients may experience a range of diverse evaluations and conclusions based upon the uncertainty. Because uncertainty surrounding health risks can affect illness perceptions and downstream behavior, understanding the consequences of uncertainty enhances the ability to describe and explain its influence on behavior and to develop intervention strategies.
A Variant of Unknown Significance (VUS) is defined as a variation in a genetic sequence whose association with disease risk is unknown (National Cancer Institute, 2016) . Therefore, it is unclear whether such sequence changes are typical variation or represent a disease-causing mutation. Such variants present a clinical interpretation challenge and also evoke counseling dilemmas. With the uptake of multigene panel testing, VUS results will be found in greater frequency (Hilbers, Vreeswijk, van Asperen, & Devilee, 2013; Yorczyk, Robinson, & Ross, 2015) . One study showed VUS rates of 25.6% among 223 patients who received an ovarian cancer focused panel (LaDuca et al., 2014) . Although it is established that a discussion of VUS is integral during pre-test and post-test genetic counseling, no established guidelines for providing clinical interpretation or recommendations exist (Blazer, 2013; Bradbury et al., 2015; Frey et al., 2015; Norquist & Swisher, 2015) .
To date, almost all of the research examining the implications of VUS genetic test results have focused on Hereditary Breast and Ovarian Cancer (HBOC) and BRCA1/2 gene testing (Culver et al., 2013; Frost, Venne, Cunningham, & Gerritsen-McKane, 2004; Murray, Cerrato, Bennett, & Jarvik, 2011; O'Neill et al., 2006; van Dijk et al., 2006; van Dijk et al., 2004; Vos et al., 2011; Vos et al., 2008) . A majority of this research is focused on uninformative test results or the receipt of a true negative result. Studies show that a subset of women with VUS results have higher distress, tend to report their results less frequently to family members, and have a harder time communicating their results compared to those with positive or true negative results (Cypowyj et al., 2009; Dorval et al., 2000; O'Neill et al., 2006; van Dijk et al., 2006) . There are limited data that describe how patients process receiving a VUS result and how this uncertainty affects the coping process. To our knowledge, this phenomenon remains unexplored in the hereditary colorectal cancer syndrome Lynch Syndrome.
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States (Siegel, Miller, & Jemal, 2015 . Although most CRC (70-80%) is sporadic, 20-30% is thought have an inherited component (O'Brien, 2000; Platz et al., 2000) . Lynch syndrome (also known as Hereditary Non-Polyposis Colorectal Cancer or HNPCC) accounts for approximately 3% of all colorectal cancer cases and is the most common inherited CRC syndrome (Aaltonen et al., 1998; Barnetson et al., 2006; Hampel et al., 2005; Pinol et al., 2005; Salovaara et al., 2000) . Lynch syndrome (LS) is an autosomal dominant cancer predisposition syndrome that significantly increases an individual's lifetime risk for colorectal cancer (52-82% by age 70) as well as other cancers including endometrial, small intestine, ovary, hepatobiliary, kidney, brain and ureter cancers (Giardiello et al., 2014; Marra & Boland, 1995) . LS is confirmed by a mutation in one of several mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) or by a mutation in the EPCAM gene. Management of the increased cancer risk falls into two main areas: increased surveillance and risk reduction through chemoprevention and/ or risk-reducing surgery (Weissman et al., 2011) . Genetic testing optimally begins with the testing of an index case who meets the revised Bethesda or Amsterdam-II criteria which focus on personal and family history of LS related cancers. Proceeding directly to testing for germline mutations in the MMR genes or the EPCAM gene is also an option. A genetic test can confirm a diagnosis of LS and will have important health implications for asymptomatic and symptomatic relatives. The purpose of this exploratory, qualitative study is to describe the experience of individuals who have received a VUS as part of the genetic testing process for LS.
Materials and Methods

Participants
Twenty seven participants were recruited from five clinical centers in the United States and Canada, through the website clinicaltrials.gov and the National Society of Genetic Counselors (NSGC) Cancer Special Interest Group (SIG) listserve. This study was reviewed and approved by The National Human Genome Research Institute Institutional Review Board. Recruitment letters were mailed to Englishspeaking adult participants over the age of 18 who received a VUS from 3 months to 10 years prior. The operational definition of VUS relied on the clinical genetic counselors at each recruitment site, and letters were only sent to those who were eligible and received a VUS based on their judgment. Each recruitment letter was accompanied by an optout questionnaire that invited potential participants to share the reasons why they would not participate. The recruitment letter outlined that the goal of the study was to understand more about the implications of receiving a VUS for Lynch Syndrome and the potential subject was invited to participate because they had received that type of genetic test result.
Procedures
Verbal informed consent was obtained by telephone prior to each interview. Participants completed a 30-45 minute semi-structured telephone interview to capture the meaning and understanding of the VUS to the participant. All interviews were conducted by one investigator (I.S.) and were recorded, and transcribed.
Mishel's Theory of Uncertainty in Illness (1988) was used as the theoretical framework to design the interview guide (Fig. 1) . According to this theory, inference and illusion are two appraisal processes used to determine the value placed on the uncertainty. Inference generally refers to the evaluation that the uncertainty will be appraised as a danger, while illusion refers to the construction of the uncertainty as an opportunity. Under the inference appraisal, coping strategies are used to reduce uncertainty, whereas illusion coping strategies will attempt to maintain uncertainty.
Data Analysis
Constructs of interest included how individuals understand their result and its meaning, and how those at risk for LS integrate their VUS into their perceived intentions and actions for medical management. Interviews addressed the following areas: the disclosure process, conceptualizing uncertainty, the appraisal of their result, coping strategies and expectation for follow-up. A pilot guide was developed prior to recruitment and modified after three pilot interviews. A codebook was developed based on the interview guide and was revised in an iterative process. I.S. and E.H. coded each transcript using Nivo software v.10 (QSR). Transcripts were explored using the constant comparison methodology of thematic analysis, which involved abstraction of the data (Glaser, 1969) . Categories derived from the data were then used to construct themes and topics to code data to establish relationships among themes (Strauss And Corbin, 1998) . Any discrepancies in coding were discussed and reconciled between coders.
Results
A total of 40 letters were mailed out with a response rate of 60% (23/40). The remaining 4 participants were recruited through clinicaltrials.gov (n = 1) and through the NSGC cancer listserve (n = 3), resulting in a sample of 27 adults that were interviewed as part of this study. Only one opt out form was returned with the explanation that the potential participant was unable to hear well over the phone. Interviews were conducted between August 2012 through December 2013. Genetic testing was performed between 2002 and 2013. A majority of participants (n = 15) were interviewed within 1 year of receiving their results, although no thematic differences were appreciated between those who had received their results closer to the time of their interview. The study sample was mostly female (n = 21), Caucasian (n = 20) and had a personal history of cancer (n = 17) ( Table 1) .
Recall
Most (n = 23) participants were aware a variant had been detected. However, four individuals did not recall their result as a VUS. Of these four individuals, two recalled their result as negative, one described her result as related to Bcolor cellsâ nd one recalled her result as negative but remembered Banomalies^were detected. The remaining 23 participants recalled their result as a VUS. For example, one participant described his VUS as the following:
BWell they can't just say that it's-this is Lynch syndrome. They can't do that. And that has something to do with that unspecified. You know there was a possibility that it could be something else, but it looks like a duck, it quacks like a duck, it's a duck, that's how this was.^(Pt. 4, 60 M, Affected with cancer (Aff.))
All 27 participants connected their genetic test results to a personal or family cancer history, for example one participant spoke to her feelings when receiving the result:
BYeah, it was a relief in yeah okay I do have something that its not my fault I got cancer and the other part of me was like this doesn't mean anything. So it's like don't be silly thinking that but I was thinking that.^(Pt. 3, 65 F, Aff.) Fig. 1 Mishel's Theory of Uncertainty in Illness (1988) Inference generally refers to the evaluation that the uncertainty will be appraised as a danger, while illusion refers to the construction of the uncertainty to be appraised as an opportunity. Under the inference appraisal, coping strategies incorporate strategies to reduce the uncertainty, whereas illusion coping strategies will attempt to maintain uncertainty Eight participants recalled tumor testing prior to germ line genetic testing, whereas only two understood tumor testing as indicating their cancer was more Bgenetic in nature^or Bshowing there was Lynch syndrome.^Some individuals felt confused by the depth and complexity of genetic or tumor testing, commenting on the amount of information, technical language, and statistics.
BNo I had no idea what that even was really. I mean like I said, our family doctor had-when you start talking about, the satellite genes and all those repair genes and all that, I mean that is you know, that's deep stuff.( Pt. 4, 60 M, Aff.)
Another respondent commented on how overwhelming it was to receive test results amidst cancer treatment:
BResponding to the results, it's hard to tease out-because there was so many other things going on with me. And it's hard to tease as-just all of this big whole situation I was in.^(Pt. 1, 57 F, Aff.)
A majority of those who recalled their result (n = 13) did not know the possibility of a VUS prior to testing, and four were unsure whether they knew a VUS was possible prior to disclosure. Affective responses ranged from relief that something was detected to shock that there was an ambiguous finding (Table 2) .
BI felt like the missing link like I was confused, I was shocked. I mean I was really shocked. I didn't get upset because what am I going to do? I can't change my genes and I really I was speechless. All I could say was "Okay, what can we do about it?" (Pt. 27, 39 F, Aff.)
Two participants felt regret about getting the genetic testing performed after receiving their result:
BI even thought to myself, BOh, why did I bother doing it? You know, because they really didn't find out anything.^(Pt. 22, 75 F)
Conceptualizing Uncertainty
The majority (n = 23) of patients conceptualized their genetic test result as one which incorporated some aspect of uncertainty. They described the uncertainty in relation to both the variant itself and in relation to their diagnosis of LS. The VUS was also described as an Bambiguity,^Bnot Participants conceptualized the uncertainty of their result within four major categories: lack of information, ambiguity, lack of diagnosis, and unpredictability (Table 3) . Ten individuals self-identified as having LS, with some qualifying their answers by stating that they had a different form of LS or that they did have LS even though their providers could not say B100 % positively.B Even the experts say it's undetermined. I would say 80 percent of the chance I have it. Even I'm not identified, I would still feel that I have a higher chance because I have that in my family history.^(Pt. 9, 40 F)
BWell, a clear positive means you have a higher percentage, right? But an unknown means you have a -it probably is like -I call it low, medium, high risk in our business, right? I put myself as a medium.^(Pt. 23, 56 F) Seven individuals said they did not have LS (including two who understood their result as a negative). Moreover, seven other individuals could not answer the question definitively:
BI will confess that even to this day, I sometimes wonder, well, do I really have Lynch syndrome? So, I've made a decision to act as if I do.^(Pt. 6, 55 F, Aff.)
Appraisals
The process of assessing the implication of the uncertainty as a dreaded or desired state is known as an appraisal. Individuals appraise a situation and determine the value placed upon the uncertainty and consider whether uncertainty is viewed as positive (opportunity) or negative (danger) (Mishel, 1988 ). An appraisal of danger (n = 17) was observed through narratives that associate the variant as a health threat, whereas the opportunity appraisal (n = 17) associates the variant with the possibility of a positive outcome or absence of a health threat (developing cancer). Narratives that were reflective of the danger appraisal generally included an interpretation of their result as a disease causing mutation. Participants described their VUS as a Bgenetic challenge,^Bgenetic mistake^, Bmutation,^Bdefect,^Bdeath sentence,^or being told Byou're going to die early.B
The implications of the result, which means, basically, on some level it's like-you know-cancer is my destiny, and I'm just a waiting, ticking time bomb for the cancers that I can't really do much to prevent.( Pt. 6, 55 F, Aff.)
Participants relied heavily on the guidance and the interpretation of their genetic counselor or provider when appraising their result.
BAfter I got the genetic result, I mean we discussed this with [genetic counselor], you know it's fairly welldocumented literature on this as well it basically from what I understood from this at least, you know the Lynch Syndrome -even though they could not tell me officially I had Lynch Syndrome but they are treating me as if I am one of the Lynch Syndrome patients^(Pt. 8, 40 M, Aff.)
They often repeated what their providers had told them or what they understood as the message from their providers. Providers' role in giving their interpretation was seen to have a major influence on the appraisal process.
BBut it turns out that the doctors think that I should keep getting the tests for cancer every year anyway, even though it isn't -even though it's a variant that has not been studied.^(Pt. 25, 58 F) When questioned on their danger appraisal, such participants responded that the strategy was safer than interpreting their result as a negative. Narratives indicated that the risk of treating their variant as benign and missing something outweighed that of treating their variant as pathogenic. Other participants had an appraisal that focused on direct action that could be taken as a result of the pathogenic mutation:
BI would rather accept it as a positive. I feel like I believe if you feel like this is a positive, not only without a basis that it is strongly positive there is some reason and also the family history there is some reason to make me think this is related to the hereditary type of disease. I would rather believe this is a positive interpretation so that way I could have a follow up plan.^(Pt. 2, 53 F, Aff.) BI think we're just trying to err on the side of taking care of things^(Pt. 4, 60 M, Aff.)
Through a few (n = 2) opportunity appraisals, the variant was appraised as a negative result:
BMy only reaction was that there was the two tests, I passed that, but that it was inconclusive because there were other tests out there. Yeah, because you had lived this -you know, you've, like, lived all this time and are sort of having that confirmation that it's negative.^(Pt. 18, 60 M ) but for most the VUS was seen as an intermediate result and thus more desirable and safer than carrying a disease causing mutation.
BIn the sense that a variant gene means it doesn't fall under a given criteria. Maybe it's just you know, something that's not different and not necessarily a On the other hand, six individuals shared narratives that reflected dual processing with elements of both the danger and the opportunity appraisal. For example, one participant considered the detection of the variant itself as a defect, and although it didn't necessarily mean anything about the future, he felt that Banother data point is not a good data point^(13) while also believing that the variant was a better result than a positive. All of these individuals believed that the presence of the variant was a health threat, but not as severe of a threat as a positive result. In that, they appraised the uncertainty as an opportunity to not have Lynch syndrome or as this participant shared:
BI feel that there is a seed of hope that I could be completely normal. Some information could come out in five years, ten years, twenty years, that could make me interpret these results differently.^(Pt. 12, 37 M)
Another dual processing participant who was adopted and did not know her family history, spoke about the uncertainty of Lynch syndrome with the danger appraisal:
BAnd getting my ovaries out, that was a hard decision but the thing is I don't want to die of something that doesn't do anything. I would rather just go ahead and get them out. I want to live. Definitley safe vs. sorry, absolutely.^(Pt. 27, 37 F, Aff.) but discussed later the hope that the VUS is benign demonstrating the opportunity appraisal:
BI hope that it means nothing. And if they find out that it means something, then proactive counseling and testing for my daughter but other than that how it stands now, I mean it doesn't mean anything right now. There is no answer.Ĉ oping Once an appraisal of a VUS is formed, coping strategies to manage the appraisal are implemented. The most common coping strategies used by study participants were categorized as mobilizing strategies (Mishel, 1988 ).
BIt's not so much as a disappointment anymore. It's become a quest. Try to help you guys as much as possible to gather many relatives that have had tumors to see if any of the stuff helps you guys to understand the gray area.^(Pt 20, 51 F, Aff.)
The most common mobilizing strategy used by all participants that appraised their variant as a danger was direct action by having a plan (n = 17).
BI would rather believe this is positive interpretation so that way I really needed to follow the plan. If I don't have one, I need to get one. I also need to make sure my son will get the proper surveillance plan for the rest of his life.^(Pt. 2, 52 F, Aff.)
BI think for me personally, like in my own mind, there would be no difference, but medically speaking I had to be a little more aggressive about being monitored because the doctors can say Bwell that's just a VUS, we don't know^and I can even say that my mom died, her mother died, had two different types of cancer, my mother's uncle, my mother's cousin, and they will still say Bthat's just a VUS.^^ (Pt. 11, 44 F) followed by reaching out to at-risk family members (n = 15), B…my niece, and I said, BListen,^you know, BHere's a heads up. Maybe you^-I emailed all the information to her and I said, BMaybe you should tell your doctor that your mother died from this genetic -what we assume was this genetic strain in the family, and just to keep an eye on her.^(Pt. 19, 57 F, Aff.)
BI was relieved to-you know just-kind of be informed that there's a plan out there to try to detect this condition, you know in-in families-and I could inform my siblings and-I shared all of my reports and everything. When I got those results, you know and-it was very helpful.^(Pt. 1, 57 F, Aff.) and seeking information (n = 6):
BI didn't want to get a second opinion because it was a big deal to get a genetic work-up, and I trusted the geneticist. I went to the Internet, though, and started doing some research on my own.^(Pt. 25, 58 F) BOh yeah, I spent a lot of time on the internet, you know just doing searches like on the National Institute of Health's, you know good reputable sites, trying to get good information as much as I could.^(Pt. 5, 65 F, Aff.)
Many participants discussed complying with the recommended cancer screening at the recommended frequency (such as colonoscopies). Themes indicated a perceived benefit from following a surveillance and management plan.
BSo that was really important for me was to kind of get in touch with that, to kind kind of you know, to realize this was happening but getting upset wasn't going to help anything. You know the thing is you need to get a plan in place, like get a surveillance plan in place, know what you're going to be doing and that gives me more comfort. To think every year, okay I'm going to have a colonoscopy and you know I'm going to let the doctors know about it, I'm going to give them literature on it, I'm going to talk to them about it and I'm going to ask my primary care doctor to set up this plan, and you know blood tests you know like once a year at this time...and that has helped a lot to kind of know that there is something in place that we're doing everything possible at this point. That's all you can do.^(Pt. 11, 44 F)
Other coping strategies included faith in a cure or optimism regarding reclassification.
BI would think ten years-ten years with today's technology we would maybe have-have that variant identified and-maybe a cure or treatment.^(Pt. 1, 57 F, Aff.) Individuals who appraised their uncertainty as a danger, felt empowered that they could take actions to reduce the health threat associated with the perceived risk:
BOnce I wrapped my head around that one then I could go on to turn it into a positive. I have the tools. I am empowered to take the best care of myself that I can for as long as I can.^(Pt. 11, 44 F) However, one individual expressed conflict over receiving a total abdominal hysterectomy and another participant expressed a dilemma over whether to have children based on the VUS.
Expectations for Reclassification
Fourteen participants expected re-classification of their VUS whereas eight viewed their VUS as unchanging. The desire to be re-contacted if more information becomes available in the future about their VUS was unanimous among all participants who recalled their VUS.
BWell, I wish that is the pattern has been identified as normal or abnormal someone would inform me. I'm hoping for that.^(Pt. 9, 40 F) BI would prefer even periodically, here is the facts, we still don't have any updated information and this is an update. Let me know the development of this. I do care especially to pass this type of information onto the family members. For generations to come they can use that information.^(Pt. 2, 53 F, Aff.)
Discussion
The purpose of this study was to explore and describe the experience of receiving a VUS for LS genetic testing. Many participants perceived the detection of the VUS as a health threat and implemented coping strategies to reduce the threat. Participants benefited greatly from having a plan of action to reduce their cancer risks despite their genetic test result. For others, the uncertainty of the VUS result also provided a seed of hope for the reclassification of their variant as benign in the future.
Studies of women who undergo BRCA gene mutation testing with an inconclusive result show disappointment in the lack of an explanation for their personal and/or family history of cancer. Consistent with one of the themes found in this study, participants felt that a definitive evaluation of their cancer risk was deemed more acceptable than unexplained uncertainty (Hallowell et al., 2002; MacDonald, Sarna, Weitzel, & Ferrell, 2010; Phelps, Wood, Bennett, Brain, & Gray, 2007) . Recent studies demonstrate that genetic counselors are comfortable explaining and disclosing VUS genetic results (Scherr, Lindor, Malo, Couch, & Vadaparampil, 2015a , 2015b . However, another study examining the comfort level of breast cancer specialists in discussing VUS found that 71% felt unsure about the health implications of such results, especially in the presence of a negative family history (Eccles, Copson, Maishman, Abraham, & Eccles, 2015; Scherr et al., 2015a Scherr et al., , 2015b . A major theme that emerged from this study is the reliance placed on provider interpretation of VUS results, underscoring the importance of providers having comfort interpreting VUS results and discussing their implications with their patients.
Evidence from this study suggests that although the majority of individuals were unaware of the possibility of a VUS result prior to genetic testing, the majority of individuals have a good understanding of their VUS result after disclosure. This phenomenon highlights the importance of providers notifying patients of the possibility for a VUS result during the informed consent process. The ability to absorb and understand complex information is related to the cognitive capacity or information-processing abilities of the person receiving the result (Babrow et al., 1998; Mishel, 1988) . It is also possible that some individuals may not have recalled being informed about the possibility of a VUS result due to being overwhelmed with the complexity of the situation. This could be the complex content of the genetic testing process and/or undergoing this process amidst receiving cancer treatment. It is also possible providers simply did not inform the patients of the possibility of a VUS result. There is evidence suggesting that physicians are hesitant to communicate uncertainty to their patients or they may also believe that communicating the complexity of uncertainty will overwhelm and confuse patients. Consequently, they de-emphasize extraneous information during the consent process (Braddock, Edwards, Hasenberg, Laidley, & Levinson, 1999; Henry, 2006) . Individuals described their VUS in ways that reflected both opportunity and danger appraisal. The meaning that the participants ascribed to the VUS seemed to be influenced by both the interpretation given by the provider and the a priori perceived controllability of LS, including early detection and curability. There is empirical evidence that psychological well-being in individuals undergoing genetic cancer susceptibility is related to perceived preventability and that individuals with LS tend to perceive a high controllability of their condition (van Oostrom et al., 2007) . Participants in the current study who appraised their result as dangerous, were generally confident in their capabilities to manage the threat of cancer. Potentially overestimating the risk of developing cancer by treating the variant as pathogenic may be seen to be accompanied by few risks. Interestingly, women in other studies who received VUS for HBOC made surgical decisions with rates that overlap with those reported for women with and without pathogenic mutations (Murray et al., 2011; Vos et al., 2011; Vos et al., 2008) . Given that individuals may undergo irreversible interventions in the presence of uncertainty, these studies highlight the importance for providers to understand the meaning and processes behind such decision-making.
The study participants used multiple kinds of mobilizing strategies to cope with the danger appraisal. These included information seeking, direct action/vigilance (CRC screening, living a healthier lifestyle), or notifying at risk family members. These coping mechanisms reduced uncertainty about the development of future cancers and the behaviors subsequently gave the participants a sense of control over their risk. The danger appraisal also elicits affective control coping strategies, which were reflected through the hope for reconciliation of their variant and reclassification in the future. These findings highlight the need for providers to recognize and assist with the appraisal process after the disclosure of a VUS.
Several participants shared concerns about their children and relatives receiving appropriate cancer screening in the context of a VUS result. Participants felt responsible to notify their family members of the variant running in their family, even if their diagnosis remained unclear. Participants also expressed that ongoing or future contact from their providers would be appreciated, even if there was no new information.
Practice Implications
The experiences reported by participants in this study have implications for clinical practice (Table 4 ). This study demonstrates the importance of additional support for patients who receive VUS genetic results due to the potential experience of negative emotions in response to an uncertain result. Providers must be prepared to support patients in understanding and managing some level of risk uncertainty and should anticipate these needs in patients who receive VUS. Han et al. (2011) emphasize the need for support and assistance in coping efforts used to manage the uncertainty that exists in • Some patients will appraise their VUS as a danger • Providers must serve as structure providers to help patients make meaning of their result • Utilization of mobilizing strategies
• Providers can facilitate the use of mobilizing strategies until the VUS is reclassified. This includes discussing follow-up care and management recommendations based on family history • Concerned about the meaning of the result for cancer screening and family members
• Work with patient to form a plan for follow-up regarding reclassification updates. Consider giving patients a time frame to check back in for updates about their VUS healthcare, instead of focusing all efforts to reduce the uncertainty through the provision of information alone. One route to provide support and assistance is through periodic communication with patients about the status of their variant even in the absence of new findings or reclassification. Providers should take into consideration that patients might have difficulty communicating their VUS and its implications to at-risk family members. Therefore, patients might benefit from interventions such as a discussion regarding potential ways to disclose and explain the significance of VUS to family members or the use of materials designed to provide family members with information about VUS results, even if genetic testing for family members would be contraindicated. Genetic counselors can assist by eliciting patients to express their concerns and fears regarding the meaning of their VUS.
Overall, participants felt that the uncertainty surrounding their result was manageable if they could implement strategies to manage their risk of developing cancer. This suggests that providers need to emphasize a plan-of-action when reporting VUS to help patients make meaning of their result. Providers might also benefit from discussing the mobilizing strategies with their patients to help them feel a sense of control about their VUS.
Study Limitations and Research Recommendations
This study is the first to examine the experience of receiving a VUS for Lynch syndrome and the first to explore the experience of receiving a VUS in depth. Owing to the small sample of 27 participants, findings were not intended to be representative of all individuals who receive a VUS for LS. Participants were recruited from several clinical sources and from two different healthcare systems, adding variation to the counseling and pre-test care they were given. While this variability allowed us to draw upon experiences beyond a single setting, the results communication process likely varied based on different provider and clinic practices. Moreover, although all participants were selected because their clinic had identified them as having received a VUS, the specifics of each case would have varied, including the non-genetic evidence for LS as well as the available information regarding the specific variant in question. We would expect that the communication process would have differed depending upon the level of uncertainty about a possible Lynch diagnosis based on other clinical details including results of tumor testing. With that said, 23 out of 27 of our participants thought of their result as a variant and described some level of uncertainty related to the result. The intent of this study was not to describe the communication process itself but rather to understand how participants are processing the perceived uncertainty associated with having received a VUS of any type. This area remains ripe for future studies, which may include exploring the impact of VUS for other hereditary cancer syndromes, as well as receiving multiple VUS which is becoming more common with the uptake of multigene panel testing.
Findings from this study also suggest that patients might benefit from explicit conversations recommending that they contact their provider periodically for updates regarding their VUS result. In fact, findings from this study suggest that patients might benefit from the responsibility of following up with their providers about their VUS status as a mobilizing strategy. It is also important to emphasize the role of the patient in alerting medical providers to changes in address, updates of their family history and to periodically request updates on their VUS status if they were not contacted.
